- Home
- DXR vs APLT Comparison
DXR vs APLT Comparison
Compare DXR & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- APLT
- Stock Information
- Founded
- DXR 1970
- APLT 2016
- Country
- DXR United States
- APLT United States
- Employees
- DXR N/A
- APLT N/A
- Industry
- DXR Medical/Dental Instruments
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- APLT Health Care
- Exchange
- DXR Nasdaq
- APLT Nasdaq
- Market Cap
- DXR 40.3M
- APLT 37.5M
- IPO Year
- DXR N/A
- APLT 2019
- Fundamental
- Price
- DXR $7.77
- APLT $0.37
- Analyst Decision
- DXR Strong Buy
- APLT Buy
- Analyst Count
- DXR 1
- APLT 7
- Target Price
- DXR $25.00
- APLT $6.10
- AVG Volume (30 Days)
- DXR 5.2K
- APLT 2.3M
- Earning Date
- DXR 01-01-0001
- APLT 04-14-2025
- Dividend Yield
- DXR N/A
- APLT N/A
- EPS Growth
- DXR 86.16
- APLT N/A
- EPS
- DXR 0.11
- APLT N/A
- Revenue
- DXR $119,714.00
- APLT $455,000.00
- Revenue This Year
- DXR N/A
- APLT $3,031.87
- Revenue Next Year
- DXR N/A
- APLT $312.01
- P/E Ratio
- DXR $71.76
- APLT N/A
- Revenue Growth
- DXR N/A
- APLT N/A
- 52 Week Low
- DXR $6.55
- APLT $0.30
- 52 Week High
- DXR $10.00
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- DXR 49.33
- APLT 42.28
- Support Level
- DXR $7.35
- APLT $0.31
- Resistance Level
- DXR $7.98
- APLT $0.38
- Average True Range (ATR)
- DXR 0.43
- APLT 0.04
- MACD
- DXR -0.00
- APLT 0.01
- Stochastic Oscillator
- DXR 52.94
- APLT 46.97
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.